Table 2.
Vemurafenib | Dabrafenib |
---|---|
Rash: 49% | Hyperkeratosis: 39% |
Photosensitivity: 31% | Photosensitivity: rare |
SCC: 19% | SCC: 10% |
Alopecia: 26% | Alopecia: rare |
Others (pruritus, dry skin, papillomas): frequent | Others (pruritus, dry skin, papillomas): not frequent |
Abbreviation: SCC, squamous cell carcinoma including keratoacanthoma.